Business
/R E P E A T -- VVT Med Receives Order from Major US Healthcare Network NorthWell Health and Enters Into Investor Relations Agreements/
/R E P E A T -- VVT Med Receives Order from Major US Healthcare Network NorthWell Health and Ente...
About this update from Vvt Med Inc.
[{"type":"text","content":"\n\n\n/R E P E A T -- VVT Med Receives Order from Major US Healthcare Network NorthWell Health and Enters Into Investor Relations Agreements/\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nVANCOUVER, BC, Oct. 29, 2025 /CNW/ - VVT Med Inc. (TSXV: VVTM) (the \"Company\" or \"VVT Med\"), a manufacturer of next-generation, minimally-invasive varicose vein treatments, is pleased to announce an initial order for several units of its flagship ScleroSafe™ technology from Northwell Health, one of the largest healthcare providers in the United States. This pivotal achievement validates the product's clinical value and marks a crucial entry into the U.S. public hospital market.  \nThe initial order will be deployed under the direction of Dr. Antonios Gasparis, Professor of Surgery and Director of the Center for Vein Care at Northwell Health. Dr. Gasparis leads one of the largest vein care programs in the United States, where his team provides a wide range of treatments for patients with venous disease. His department's evaluation of ScleroSafe™ is expected to inform potential future use across Northwell's system.\nNew York-based Northwell Health is one of the USA's largest health care networks, with over 100,000 employees at 28 hospitals and 1,000+ clinics. Northwell also operates one of the nation's leading vein programs. VVT's patented solution will enable Northwell to streamline varicose vein procedures without requiring anesthetics or capital investment.\n\"Only 2% of symptomatic varicose vein patients undergo treatment, largely due the lack of ideal solutions in the market, awareness, and fear of pain and potential complications involved in current procedures. VVT's ScleroSafe™ enables these treatments to be completed in a more accessible manner, minimizing pain and post procedure care,\" said Erez Tetro, CEO of VVT.\nThe Company believes this milestone validates the competitive differentiation of its technology and its ability to meet the standards of a top-tier U.S. health system. It positions VVT for future growth within th...